195 related articles for article (PubMed ID: 33782049)
21. Surveillance in Barrett's esophagus: an audit of practice.
Ajumobi A; Bahjri K; Jackson C; Griffin R
Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
[TBL] [Abstract][Full Text] [Related]
22. Endoscopic laser ablation of nondysplastic Barrett's epithelium: is it worthwhile?
Bonavina L; Ceriani C; Carazzone A; Segalin A; Ferrero S; Peracchia A
J Gastrointest Surg; 1999; 3(2):194-9. PubMed ID: 10457346
[TBL] [Abstract][Full Text] [Related]
23. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
[TBL] [Abstract][Full Text] [Related]
24. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
25. AGA Clinical Practice Update on Endoscopic Treatment of Barrett's Esophagus With Dysplasia and/or Early Cancer: Expert Review.
Sharma P; Shaheen NJ; Katzka D; Bergman JJGHM
Gastroenterology; 2020 Feb; 158(3):760-769. PubMed ID: 31730766
[TBL] [Abstract][Full Text] [Related]
26. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A.
Fossmark R; Sørdal Ø; Jianu CS; Qvigstad G; Nordrum IS; Boyce M; Waldum HL
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1067-75. PubMed ID: 23072686
[TBL] [Abstract][Full Text] [Related]
27. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
Goodarzi M; Correa AM; Ajani JA; Swisher SG; Hofstetter WL; Guha S; Deavers MT; Rashid A; Maru DM
Mod Pathol; 2009 Dec; 22(12):1612-21. PubMed ID: 19734842
[TBL] [Abstract][Full Text] [Related]
28. Esophageal adenocarcinoma arising in cervical inlet patch with synchronous Barrett's esophagus-related dysplasia.
Tanaka M; Ushiku T; Ikemura M; Shibahara J; Seto Y; Fukayama M
Pathol Int; 2014 Aug; 64(8):397-401. PubMed ID: 25143128
[TBL] [Abstract][Full Text] [Related]
29. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.
Ishimura N; Amano Y; Sanchez-Siles AA; Fukuhara H; Takahashi Y; Uno G; Tamagawa Y; Mishima Y; Yuki T; Ishihara S; Kinoshita Y
J Clin Gastroenterol; 2011 Sep; 45(8):665-72. PubMed ID: 21325951
[TBL] [Abstract][Full Text] [Related]
30. The Role of Acid Suppression in Barrett's Esophagus.
Elias PS; Castell DO
Am J Med; 2017 May; 130(5):525-529. PubMed ID: 28159599
[TBL] [Abstract][Full Text] [Related]
31. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
[TBL] [Abstract][Full Text] [Related]
32. Endoscopic Treatment of Early Barrett's Adenocarcinoma and Dysplasia: Focus on Submucosal Cancer.
Frei N; Frei R; Semadeni GM; Jochum W; Brand S; Borovicka J
Digestion; 2019; 99(4):293-300. PubMed ID: 30176662
[TBL] [Abstract][Full Text] [Related]
33. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus.
Fitzgerald RC; Saeed IT; Khoo D; Farthing MJ; Burnham WR
Dig Dis Sci; 2001 Sep; 46(9):1892-8. PubMed ID: 11575441
[TBL] [Abstract][Full Text] [Related]
34. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
[TBL] [Abstract][Full Text] [Related]
35. Multilayered epithelium may be found in patients with Barrett's epithelium and dysplasia or adenocarcinoma.
Upton MP; Nishioka NS; Ransil BJ; Rosenberg SJ; Puricelli WP; Zwas FR; Shields HM
Dig Dis Sci; 2006 Oct; 51(10):1783-90. PubMed ID: 16967312
[TBL] [Abstract][Full Text] [Related]
36. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
37. Large intra- and inter-individual variability of genes expression levels limits potential predictive value of molecular diagnosis of dysplasia in Barrett's esophagus.
Hennig EE; Mikula M; Orlowska J; Jarosz D; Bielasik A; Regula J; Ostrowski J
J Mol Med (Berl); 2008 Feb; 86(2):233-42. PubMed ID: 17952395
[TBL] [Abstract][Full Text] [Related]
38. [Endoscopic diagnosis of Barrett's adenocarcinoma].
Yoshio H; Takashi Y; Mitsuyo H; Nobuhiko Y; Tatsurou T; Kazuhiko S; Yoko H; Shigemasa I; Hisanaga M; Osamu H; Katsuyoshi S; Seishi U; Matsushita H; Masahiko T
Nihon Geka Gakkai Zasshi; 1999 Mar; 100(3):244-8. PubMed ID: 10379534
[TBL] [Abstract][Full Text] [Related]
39. Dysplasia in Barrett's esophagus. A clinicopathologic study of six patients.
Lee RG
Am J Surg Pathol; 1985 Dec; 9(12):845-52. PubMed ID: 2416226
[TBL] [Abstract][Full Text] [Related]
40. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus.
Weston AP; Krmpotich PT; Cherian R; Dixon A; Topalosvki M
Am J Gastroenterol; 1997 Mar; 92(3):407-13. PubMed ID: 9068459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
